DadFinStart your free week
DadFin › Stocks › Basic Materials › MNTK

Montauk Renewables, Inc. (MNTK) stock score

Basic Materials · Specialty Chemicals · United States

$2.53 ▼ -7.66% today

55.2
Dad Score, out of 100
middling

Montauk Renewables, Inc. (MNTK) is a Specialty Chemicals company in the Basic Materials sector, listed in the United States. On DadFin's weekly run it scores 55.2 out of 100 on the Dad Score, a middling reading that places the business ahead of 55% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Basic Materials it ranks #148 of 397. Its strongest axes are price action and liquidity; its weakest are valuation and quality.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Below average
Quality
Below average
Growth
Below average
Price action
Strong
Risk
Below average
Conviction
Average
Liquidity
Strong
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)57.4×
P/E (forward)9.4×
Dividend yield0.00%
Return on capital0.6%
Operating margin1.1%
Revenue growth (YoY)+0.4%
FCF yield-16.8%
Net debt / EBITDA3.72×
Piotroski F-Score3 / 9
52-week change+25.9%
Market cap$409M
Next earnings—

What subscribers see on MNTK

Start your free weekSubscriber? Open the full research →

Specialty Chemicals peers

StockCompanyDad ScoreBandMarket cap
LINLinde plc96.5strong$221.0B
SHWThe Sherwin-Williams Company37.1weak$77.6B
ECLEcolab Inc.39.1weak$76.7B
APDAir Products and Chemicals, Inc.30.4weak$61.8B
PPGPPG Industries, Inc.62.5middling$23.4B
IFFInternational Flavors & Fragrances14.4poor$21.0B
LYBLyondellBasell Industries N.V.28.3weak$18.9B
SQMSociedad Química y Minera de Chile51.9middling$18.4B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.